Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct.”
Cassava Sciences SAVA stock was down nearly 40% in after-hours trading.
Science…
This post was originally published on Market Watch
